Q1 2022

Filed May 13, 2022 · 10-Q · 43 days after period end · 0001213900-22-026061

Q1 2022 · 10-Q

Revenue—

Net Income

-$720.01K

no prior Q1 2021 on file

EPS, diluted—

Operating Income-$801,048—

Operating Cash Flow-$98,165—

Same quarter

no prior Q1 2021 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Mar 31, 2022 · filed May 13, 2022 · 43 d after period end

ZyVersa Therapeutics, Inc. · CIK 1859007 · Engraved from SEC EDGAR